NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
BioAtla, Inc. BCAB
7 fiscal years on record · USD · FY2025 reported · SEC filings only
$-59.6M
Growth
—
Revenue, FY2025 · full 7-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2024 · ROE -164.3%
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | 0.0 | · | · |
| Operating income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | −1.01 | −1.44 | −2.58 | −2.74 | −2.76 | −3.19 | · |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · |
| ROE % | · | −164.3 | −98.4 | −54.4 | −45.3 | −17.1 | · |
| Shares out B | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures in 25 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 51 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019